These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26071630)

  • 1. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.
    Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM
    J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.
    Simón-Gracia L; Hunt H; Scodeller P; Gaitzsch J; Kotamraju VR; Sugahara KN; Tammik O; Ruoslahti E; Battaglia G; Teesalu T
    Biomaterials; 2016 Oct; 104():247-57. PubMed ID: 27472162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
    Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
    Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-penetrating iRGD peptide inhibits metastasis.
    Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
    Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
    Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
    Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter arterial chemoembolization (TACE) with iRGD peptide in rabbit VX2 liver tumor.
    Liu X; Xie Y; Qi X; Xu K
    J Cancer Res Ther; 2020; 16(7):1703-1709. PubMed ID: 33565520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
    Schmithals C; Köberle V; Korkusuz H; Pleli T; Kakoschky B; Augusto EA; Ibrahim AA; Arencibia JM; Vafaizadeh V; Groner B; Korf HW; Kronenberger B; Zeuzem S; Vogl TJ; Waidmann O; Piiper A
    Cancer Res; 2015 Aug; 75(15):3147-54. PubMed ID: 26239478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.
    Zhong Y; Su T; Shi Q; Feng Y; Tao Z; Huang Q; Li L; Hu L; Li S; Tan H; Liu S; Yang H
    Int J Nanomedicine; 2019; 14():8543-8560. PubMed ID: 31802868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.
    Hunt H; Simón-Gracia L; Tobi A; Kotamraju VR; Sharma S; Nigul M; Sugahara KN; Ruoslahti E; Teesalu T
    J Control Release; 2017 Aug; 260():142-153. PubMed ID: 28603028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?
    Zhang WQ; Yu KF; Zhong T; Luo LM; Du R; Ren W; Huang D; Song P; Li D; Zhao Y; Wang C; Zhang X
    J Drug Target; 2015 Dec; 23(10):897-909. PubMed ID: 26087869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin.
    Rossi CR; Mocellin S; Pilati P; Foletto M; Quintieri L; Palatini P; Lise M
    Surg Oncol Clin N Am; 2003 Jul; 12(3):781-94. PubMed ID: 14567031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
    Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Greenwald DR; Ruoslahti E
    Science; 2010 May; 328(5981):1031-5. PubMed ID: 20378772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.
    Sidorenko V; Scodeller P; Uustare A; Ogibalov I; Tasa A; Tshubrik O; Salumäe L; Sugahara KN; Simón-Gracia L; Teesalu T
    Sci Rep; 2024 Jul; 14(1):17513. PubMed ID: 39080306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.
    Gu G; Gao X; Hu Q; Kang T; Liu Z; Jiang M; Miao D; Song Q; Yao L; Tu Y; Pang Z; Chen H; Jiang X; Chen J
    Biomaterials; 2013 Jul; 34(21):5138-48. PubMed ID: 23582684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
    Zhang Q; Zhang Y; Li K; Wang H; Li H; Zheng J
    PLoS One; 2015; 10(6):e0129865. PubMed ID: 26066322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
    Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
    Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis.
    Kim J; Shim MK; Cho YJ; Jeon S; Moon Y; Choi J; Kim J; Lee J; Lee JW; Kim K
    Biomaterials; 2021 Dec; 279():121189. PubMed ID: 34695659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.
    Simón-Gracia L; Hunt H; Scodeller PD; Gaitzsch J; Braun GB; Willmore AM; Ruoslahti E; Battaglia G; Teesalu T
    Mol Cancer Ther; 2016 Apr; 15(4):670-9. PubMed ID: 26880267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis.
    Detroz B; Laurent S; Honoré P; Blaffart F; Limet R; Meurisse M
    Acta Chir Belg; 2004 Aug; 104(4):377-83. PubMed ID: 15469146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.